Home
Home

IPF

Rejection of InterMune’s Drug Told Early to FDA Advisers

Rejection of InterMune’s Drug Told Early to FDA Advisers
Bloomberg

InterMune Gearing Up For Another Round With The FDA

InterMune Gearing Up For Another Round With The FDA
Yahoo/Reuters

InterMune's Esbriet rings up $2.8 million in sales since mid-September launch in Germany

InterMune's Esbriet rings up $2.8 million in sales since mid-September launch in Germany
Yahoo/AP

News

InterMune Surges on EC Drug Approval
Barron's

News

5 Drugmakers Headed Back to the Drawing Board
Motley Fool

News

InterMune to start new IPF drug trial
Bizjournals

News

Gilead ends trial of lung disease drug candidate
Yahoo/AP

News

Gilead to Buy Arresto Biosciences for $225 Million to Obtain Lung Medicine
Bloomberg

News

FibroGen: Drug could reduce lung fibrosis
Bizjournals.com
»

News

InterMune Batting .500
Motley Fool
»